Highlights NanoViricides, Inc.

Equities

NNVC

US6300873022

Market Closed - Nyse Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
1.72 ^USD	-0.58%		-5.49%	+68.63%

06-20	Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model	CI
06-11	Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model	06-20	CI
Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect	06-11	CI
NanoViricides, Inc. Reports on the Highly Desirable Blood Concentration Profile of its Lead Clinical Stage Broad-Spectrum Antiviral Agent NV-387 Upon Intravenous	06-04	CI
NanoViricides, Inc. Intends to Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More	05-29	CI
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-15	CI
NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV	05-14	CI
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	05-08	CI
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Influenza A	05-06	CI
NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon	04-30	CI
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-14	CI
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	02-01	CI
Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found	01-29	CI
NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2	11-28	CI
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development	11-14	CI
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	13/10/23	CI
Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2	21/08/23	CI
Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides	11/07/23	CI
Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well	06/07/23	CI
Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun	29/06/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NanoViricides, Inc.

Equities

NNVC

US6300873022

Highlights

Filters